-
RBC Capital Reiterates Outperform Rating on Contineum Therapeutics (CTNM)
-
Leerink Partners Starts Contineum Therapeutics (CTNM) at Outperform
-
Contineum Therapeutics, Inc. (CTNM) Misses Q2 EPS by 34c
-
Contineum Therapeutics (CTNM) Provides Update on Phase 1b Positron Emission Tomography Trial of PIPE-791
-
William Blair Starts Contineum Therapeutics (CTNM) at Outperform
-
Contineum Therapeutics, Inc. (CTNM) Misses Q1 EPS by 20c
-
Contineum Therapeutics (CTNM) Files $300M Mixed Shelf
-
Contineum Therapeutics (CTNM) Appoints Diego Miralles to its Board
-
Contineum Therapeutics, Inc. (CTNM) Misses Q4 EPS by 11c
-
Contineum Therapeutics (CTNM) Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
-
Contineum Therapeutics (CTNM) Expands Clinical Development of PIPE-791
-
Baird Starts Contineum Therapeutics (CTNM) at Outperform
-
Stifel Reiterates Buy Rating on Contineum Therapeutics (CTNM)
-
Contineum Therapeutics, Inc. (CTNM) Misses Q2 EPS by 3c
-
Contineum Therapeutics (CTNM) PT Raised to $32 at RBC Capital

